12 Health Care Stocks Moving In Friday's Intraday Session

Benzinga · 06/06 17:06
Gainers
- Phathom Pharmaceuticals (NASDAQ:PHAT) stock rose 85.8% to $8.71 during Friday's regular session. The company's market cap stands at $606.9 million.
- Know Labs (AMEX:KNW) shares rose 54.86% to $0.79. The market value of their outstanding shares is at $5.9 million.
- Bluejay Diagnostics (NASDAQ:BJDX) shares rose 48.68% to $2.26. The market value of their outstanding shares is at $3.3 million.
- China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 39.16% to $1.86. The company's market cap stands at $48.5 million.
- BioSig Technologies (NASDAQ:BSGM) stock moved upwards by 38.76% to $7.96. The market value of their outstanding shares is at $217.4 million.
- NuCana (NASDAQ:NCNA) stock moved upwards by 29.87% to $0.05. As per the news, the Q1 earnings report came out 4 days ago.
Losers
- Vera Therapeutics (NASDAQ:VERA) shares fell 29.0% to $21.74 during Friday's regular session. The market value of their outstanding shares is at $1.3 billion.
- Scinai Immunotherapeutics (NASDAQ:SCNI) stock fell 24.62% to $2.45. The market value of their outstanding shares is at $2.2 million.
- Accuray (NASDAQ:ARAY) shares declined by 15.17% to $1.29. The market value of their outstanding shares is at $132.8 million.
- Cyclacel Pharmaceuticals (NASDAQ:CYCC) shares decreased by 15.1% to $0.51. The company's market cap stands at $12.2 million.
- Evoke Pharma (NASDAQ:EVOK) shares fell 13.4% to $3.0. The company's market cap stands at $4.4 million.
- Nuwellis (NASDAQ:NUWE) stock declined by 13.39% to $0.53. The market value of their outstanding shares is at $2.3 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.